Q-omics provides the consensus-scored OTUD3 profile across patient tissues and cancer cell-line models. OTUD3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OTUD3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, OTUD3 RNA expression shows 21,229 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where OTUD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTUD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTUD3 survival associations across molecular data types. OTUD3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTUD3 RNA expression–survival associations across cancer types. High OTUD3 expression shows unfavorable associations in ACC, KICH, LIHC and LGG, but favorable associations in SCLC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OTUD3 RNA expression.
This table summarizes OTUD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OTUD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTUD3 shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, COAD, STAD and CHOL. The KICH box plot shows higher OTUD3 RNA expression in normal versus tumor tissue (log2 FC = −0.711, t-test p < 0.001).
This table shows molecular features associated with OTUD3 in patient tissues and cancer cell lines. In patient samples, OTUD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, OTUD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
